Metyrapone in treatment-resistant depression
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Depression affects a significant proportion of the population, with 1-year and lifetime prevalence of 3–5% and 10–30% respectively. Full remission is achieved in only a third of patients following treatment with first-line antidepressant. There is a need for novel treatments for treatment-resistant depression (TRD). Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis has been described in patients with depression. There is persistent rise in the levels of cortisol (end product of the HPA axis) and impairment of the negative feedback inhibition mechanism of the HPA axis. Dysregulation of the HPA axis has been found to be linked to nonresponse to antidepressants and relapse following successful treatment. The efficacy of pharmacological agents that intervene with the mechanisms involved in dysregulation of cortisol synthesis and release are being explored in depression, particularly in TRD. Studies have been carried out with these drugs as augmenting agents for antidepressants or as monotherapy. The strongest evidence has come from studies using metyrapone, a cortisol synthesis inhibitor, and this has been described in detail in this review. The most robust evidence for its antidepressant efficacy in depression comes from a double-blind, randomized, placebo-controlled study of augmentation of serotonergic antidepressants with metyrapone. A 3-week augmentation of serotonergic antidepressants with 1 g metyrapone daily was shown to be superior to placebo in reducing the Montgomery–Asberg Depression Rating Scale by 50%, 5 weeks following initiation of treatment. The mechanism of the antidepressant action of metyrapone is not clear but the evidence for various potential mechanisms is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Hasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1097 · Cited by 1,645
Prevalence and incidence studies of anxiety disorders: A systematic review of the literature
Somers, J. M., Goldner, E. M., Waraich, P., & Hsu, L. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100206 · Cited by 1,114
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
Prevalence and Incidence Studies of Mood Disorders: A Systematic Review of the Literature
Waraich, P., Goldner, E. M., Somers, J. M., & Hsu, L. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900208 · Cited by 522 · cited 3×
“It has been reported to have a 1-year prevalence of 3–5% [Hasin et al. 2005; Waraich et al. 2004] and a lifetime prevalence varying from 10 to 30% [Hasin et al. 2005; Waraich et al. 2004].”
BackgroundZobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354
Deuschle, M., Schweiger, U., Weber, B., Gotthardt, U., Körner, A., Schmider, J., Standhardt, H., Lammers, C.-H., & Heuser, I. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3689 · Cited by 344
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Zimmermann, P., Brückl, T., Nocon, A., Pfister, H., Binder, E. B., Uhr, M., Lieb, R., Moffitt, T. E., Caspi, A., Holsboer, F., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111577 · Cited by 262
Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain
Patel, P. D., Lopez, J. F., Lyons, D. M., Burke, S., Wallace, M., & Schatzberg, A. F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00035-2 · Cited by 252 · cited 1×
“Regions of high MR mRNA levels include all hippocampal pyramidal cell fields, dentate gyrus granule cell layer, lateral septum, medial and lateral amygdala, and to a lesser extent, cerebellum [Patel et al. 2000].”
BackgroundClinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300884 · Cited by 203 · cited 2×
“…findings in the initial open studies [Belanoff et al. 2001, 2002; Simpson et al. 2005] and randomized controlled trials [DeBattista et al. 2006; Flores et al. 2006] have been followed by a larger negative trial [Blasey et al. 2011], which used reduction in psychotic symptoms as the outcome…”
ResultNot fade away: the HPA axis and depression
Cowen, P. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709005558 · Cited by 191 · cited 2×
“It has been repeatedly shown that there is dysregulation of the HPA axis in depression [Cowen, 2010; McAllister-Williams et al. 1998].”
BackgroundMetyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184 · cited 6×
“In a blinded study on patients with TRD, in which metyrapone was used alongside serotonergic antidepressants, only headaches and nausea were reported more frequently by participants in the metyrapone group compared with the placebo group [Jahn et al. 2004].”
BackgroundMethodResultInfluentialDeBattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R. L., Blasey, C., Carpenter, L. L., & Alva, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.034 · Cited by 162 · cited 2×
“…patients with pMDD. Positive findings in the initial open studies [Belanoff et al. 2001, 2002; Simpson et al. 2005] and randomized controlled trials [DeBattista et al. 2006; Flores et al. 2006] have been followed by a larger negative trial [Blasey et al. 2011], which used reduction in psychotic…”
ResultAppelhof, B. C., Huyser, J., Verweij, M., Brouwer, J. P., van Dyck, R., Fliers, E., Hoogendijk, W. J. G., Tijssen, J. G. P., Wiersinga, W. M., & Schene, A. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.008 · Cited by 154 · cited 2×
“2001] and relapse following successful treatment [Appelhof et al. 2006; Aubry et al. 2007].”
BackgroundOtte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K., & Kellner, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.10.006 · Cited by 129 · cited 1×
“Otte and colleagues found that patients with depression who had their serotonergic antidepressant augmented with a MR agonist (fludrocortisone) responded faster than those who had their medication augmented with a MR antagonist (spironolactone) or placebo [Otte et al. 2010].”
BackgroundVelders, F. P., Kuningas, M., Kumari, M., Dekker, M. J., Uitterlinden, A. G., Kirschbaum, C., Hek, K., Hofman, A., Verhulst, F. C., Kivimaki, M., et al. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.01.003 · Cited by 106
Relationship of cortisol hypersecretion to brain CT scan alterations in depressed patients
Kellner, C. H., Rubinow, D. R., Gold, P. W., & Post, R. M. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90062-8 · Cited by 98 · cited 1×
“There is evidence of a blunted ACTH response to CRH and of an increased cortisol response to ACTH in depression [Kellner et al. 1983].”
BackgroundTreatment of major depression with steroid suppressive drugs
Pearson Murphy, B. E. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90069-h · Cited by 67 · cited 1×
“Murphy described a case report of a patient with TRD responding to metyrapone and aminoglutethimide who remained in remission for more than 2 years [Murphy, 1991].”
BackgroundSimpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0509 · Cited by 63
Cited by
An active inference theory of allostasis and interoception in depression
Barrett, L. F., Quigley, K. S., & Hamilton, P. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0011 · Cited by 554
The role of neuroinflammation on pathogenesis of affective disorders
Rhie, S. J., Jung, E.-Y., & Shim, I. (2020) · Journal of Exercise Rehabilitation · doi:10.12965/jer.2040016.008 · Cited by 126
Faridhosseini, F., Sadeghi, R., Farid, L., & Pourgholami, M. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2401 · Cited by 89
Kvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86
“There is clinical evidence that MET enhances antidepressant response (Sigalas et al. 2012; McAllister-Williams et al. 2013) and is effective as a stand-alone therapy in hypercortisolemic patients with depressive symptoms (Jeffcoate et al.”
Background
Metadata
- Authors
- Sigalas, P. D., Garg, H., Watson, S., McAllister-Williams, R. H., & Ferrier, I. N.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-03-27
- Volume
- 2
- Issue
- 4
- Pages
- 139-149
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2158655086
- Cited by
- 40
- References
- 22
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.